Clinical Trial Update: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer [Phase 2, Phase 3]

View source ↗

Summary

A perioperative trial investigating the combination of SOX chemotherapy with Apatinib and Camrelizumab for gastric and gastroesophageal junction adenocarcinoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Ruijin Hospital | Conditions: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING